Open | $15.800 |
Close | $15.600 |
Volume / Avg. | 1.552M / 1.357M |
Day Range | 15.270 - 16.380 |
52 Wk Range | 4.290 - 21.880 |
Market Cap | $973.939M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 42 |
Short Interest | 12.46% |
Days to Cover | 4.01 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Macrogenics (NASDAQ: MGNX) through any online brokerage.
Other companies in Macrogenics’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), Cabaletta Bio (NASDAQ:CABA), Zentalis Pharma (NASDAQ:ZNTL), Centessa Pharmaceuticals (NASDAQ:CNTA) and Tango Therapeutics (NASDAQ:TNGX).
The latest price target for Macrogenics (NASDAQ: MGNX) was reported by Citigroup on Monday, March 11, 2024. The analyst firm set a price target for 25.00 expecting MGNX to rise to within 12 months (a possible 60.26% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Macrogenics (NASDAQ: MGNX) is $15.6 last updated March 18, 2024 at 4:20 PM EDT.
There are no upcoming dividends for Macrogenics.
Macrogenics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Macrogenics.
Macrogenics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.